Context: Reduced longevity observed in hypopituitarism has been attributed to GH deficiency (GHD). It is, however, unclear whether GHD or other confounding factors cause this early mortality.
H
uman longevity results from a multifactorial interaction between environment and genetics. Genetic factors are thought to be responsible for approximately 20 to 30% of life span (1) with several candidate genes identified over the years. One system involved in longevity is the GH-IGF-I/insulin pathways. Disruption of the insulin signaling is associated with increased life expectancy in nematodes (2) , yeast (3) , and insects (4) . In higher organ-isms that have a separate GH-IGF-I axis, like mice (5-7), dogs (8) , and possibly humans (9, 10) , disruption of this axis at different levels also causes increased life span. Indeed, very recently Suh et al. (11) have shown in centenarians an overrepresentation of heterozygous mutations in the IGF-I receptor gene that cause reduction of intracellular signaling, confirming that genetic alterations in this system can confer increased longevity.
On the other end, aging is associated with a progressive reduction of GH secretion and serum IGF-I, a process often called "somatopause." Furthermore, GH deficiency (GHD) in young adults causes changes that are strikingly similar to the ones observed during aging: reduction in muscle mass and strength, bone mineral density, and quality of life; increased abdominal adiposity, insulin resistance, and total and low-density lipoprotein (LDL)-cholesterol (12) . GH therapy can revert some of the changes associated with aging and many of the features of adult GHD (13) . Furthermore, in a landmark study, Rosén et al. (14) reported increased vascular mortality in hypopituitary patients with likely but nonproven GHD.
Hence, there is a paradox that, whereas some studies show that dampening of the GH-IGF axis increases longevity, GHD is associated with features commonly seen in aging and increased mortality. Because most cases of GHD occur in panhypopituitary patients who have often undergone pituitary surgery and/or radiation, it remains yet unclear whether this increased cardiovascular mortality results from untreated GHD or from these confounding factors. Definitive studies on the effects of GHD should be performed in patients with isolated GHD (IGHD), but this disorder is rare and most often treated. We have identified a large extended pedigree with more than 100 individuals (over several generations) affected by familial IGHD and residing in Itabaianinha County, a rural area in the northeastern Brazilian State of Sergipe. They all carry a homozygous null mutation (IVS1 ϩ 1G3 A) in the GHRH receptor gene (GHRH-R) (15) . Recently, we have reported that heterozygous carriers of this mutation have normal height but reduction in body weight and increase of insulin sensitivity that may also influence longevity (16) .
The purpose of this work is to study the longevity in both homozygous and heterozygous carriers of the Itabaianinha GHRHR mutation.
Subjects and Methods

Longevity in IGHD individuals
Working in this community for 15 yr, we have identified a large number of IGHD subjects. Their adult phenotype is unmistakable, with final stature ranging from 117 to 137 cm in males and from 107 to 126 cm in females, peculiar facial appearance, and characteristically high pitched voice. All the living IGHD individuals were genotyped and proven to be homozygous for the IVS1 ϩ 1G3 A GHRH-R mutation. For the deceased subjects who could not be genetically tested, we interviewed family members to rule out the presence of dysmorphic features that may indicate achondroplasia or other chondrodysplasias that may cause non-GH-related dwarfism. We are confident that the high degree of familiarity of the Itabaianinha population with the typical phenotype of untreated IGHD would have allowed us to determine from history whether any atypical feature was present. No subjects with dysmorphic features were identified.
To study longevity in IGHD individuals, we collected the date of birth of all the living IGHD individuals from Itabaianinha and their unaffected siblings, and the date and cause of death (categorized in cancer, cardiovascular, external, infectious, and unknown groups) for those who have died. Children aged less than 4 yr were not included due the difficulty of the diagnosis of IGHD before this age by physical exam (growth failure starts in the first year of life, but it becomes more evident as children age). Data were obtained from birth certificates, identity cards, and death certificates. When such documents were not retrievable, a verbal questionnaire was administered to family members. The cause of death was deemed to be "unknown" unless there was a certificate of death or other medical documents, such as hospital records, medications prescription, or previous reports of diseases. We identified 75 IGHD individuals, 53 alive and 22 deceased, who were born between 1892 and 1997. Because the dwarfism in Itabaianinha has been documented for approximately 200 yr, data of some individuals who died in the remote past could not be retrieved.
For 10 of the deceased IGHD individuals, it was not possible to identify any sibling. Analyses comparing the IGHD to their siblings are from 34 families with 65 IGHD individuals (53 alive and 12 dead) and 129 unaffected siblings (112 alive and 17 dead).
We also collected death certificates of individuals from the general population from 1964 (the year of the first registered IGHD death) to 2006 (the year of the latest IGHD death). In this period, 22 IGHD deaths (the 12 included in the comparison between GHD and siblings, and the 10 excluded from that analysis) and 4266 deaths in the general population were registered. For the comparison between GHD and the general population, we selected individuals matched by sex from the general population who were born in the same years as the 22 deceased IGHD subjects, forming a group of 522 individuals.
Statistical methods
Comparison of GHD subjects and unaffected siblings
A retrospective cohort study was performed to compare Kaplan-Meier survival curves for the GHD and their siblings for all individuals and stratified by sex. Curves were constructed for all ages and separately for those who survived to age 20. Survival curves were compared between groups with a log rank statistic, and mortality risk was quantified with hazard ratios (HRs) and 95% confidence intervals. For this comparison, a robust SE was estimated to account for the clustering within families. Life span (defined as age of death) was compared between deceased individuals from both groups for all individuals and stratified by sex with a linear regression model that used generalized estimating equations to account for the correlation among individuals from the same family.
Comparison of GHD subjects and the general population
Age of death was categorized into five groups: 4 -20, 21-40, 41-60, 61-80, and over 80 yr. The frequencies of deaths within these five age categories and differences in causes of death were compared between the IGHD individuals and the general population using Fisher's exact test. Life span was analyzed and compared between all individuals and also stratified by sex with a t test. All analyses were performed with statistical software R v2.9.0 (www.rproject.org).
Longevity in the heterozygous carriers of the mutation
Because heterozygosity is not associated with an easily identifiable phenotype, we needed to use a different approach than the one we used for the IGHD subjects. A transversal study was carried out to compare the rate of heterozygosity for the GHRH-R gene mutation in two groups of normal-appearing subjects of different ages-young (20 -40 yr) and old (60 to 80 yr) residing in Itabaianinha County. We reasoned that, if heterozygosis changes life expectancy, the prevalence of the mutation will be different in the two groups. This approach can be used in this population because their mobility is close to zero. To avoid the influence of this allele to be buffered by other genes that may strongly influence life span, we did not include individuals with an extremely long life span (Ͼ80 yr). Based on the fact that there are at least 70 live homozygous IGHD-affected subjects in a population of 32,000 (incidence 2.1/1000), the predicted number of heterozygous individuals calculated with the Hardy-Weinberg formula (p 2 ϩ 2pq ϩ q 2 ϭ 1) is 2852 (8.9%). We calculated that, even if the prevalence of heterozygosity was 7.5%, to detect a 7.5% difference in prevalence of the mutated allele with ␣ ϭ 0.05 and a power of 0.8 we would have needed to genotype 278 subjects in each group. To avoid overrepresentation of heterozygous subjects, we did not include subjects who are first-or seconddegree relatives of a GHD subject. Advertising by broadcast and loud speakers, we invited people to volunteer on the day of the October 2008 municipal election. A total of 793 subjects volunteered, 456 young (233 males and 223 females) and 340 old (183 males and 144 females). They were all genotyped from buccal swabs.
Genotyping of IVS1 ϩ 1G3 A mutation (rs2302022) was performed using predesigned TaqMan SNP Genotyping Assay C_15757069_10 (Applied Biosystems, Foster City, CA). PCR and endpoint detection of fluorescence was carried out in an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) following the manufacturer's supplied protocols. Genotyping was successful in all the subjects except three old ones, bringing their number to 337. A 2 test was used to compare the rates of the IVS1 ϩ 1G3 A heterozygous change (A/G) and of the normal homozygous (G/G) in the young and old groups.
Institutional Review Boards of both the Johns Hopkins University and the Federal University of Sergipe approved the protocol. Written informed consent was obtained from all the patients who underwent genotyping.
Results
Longevity in GHD individuals
The risk of death was not significantly different between IGHD and their siblings at all ages [HR ϭ 0.61 (95% confidence interval, 0.27, 1.42); log rank P ϭ 0.26]. Kaplan-Meier survival curves comparing IGHD subjects and their siblings (males and females together) at all ages are shown in Fig. 1A (log rank P ϭ 0.26) and from age 20 in Fig 1B (log rank P ϭ 0.55) ; for male IGHD and brothers at all ages in Fig. 1C (log rank P ϭ 0.15) and from 20 yr in Fig. 1D (log rank P ϭ 0.25); for female IGHD and sisters at all ages in Fig. 1E (log rank P ϭ 0.7) and from 20 yr in Fig. 1F (log rank P ϭ 0.81). The oldest death of an IGHD individual occurred at age 88. As of 2006, there were seven living IGHD subjects in Itabaianinha aged above 70 yr, including an 84-yr-old male and a 93-yr-old female.
The comparison of the frequency of deaths in IGHD individuals and the general population, grouped by age of death (Table 1) , showed a high frequency of IGHD deaths in females aged 4 -20. Table 2 shows life span, defined as age of death among deceased individuals, for the whole group of IGHD individuals, their unaffected siblings, and the general population, stratified by sex, and among all individuals and those who reached age 20. We found that IGHD females have a shorter life span compared with the general population, but not to their unaffected sisters. Male IGHD have a shorter life span than unaffected brothers. However, when we looked at subjects who reached age 20, we observed no difference in life span between IGHD subjects and their siblings or the general population. There were no significant differences in the causes of death between IGHD and the general population (Table 3) .
Longevity in heterozygous carriers
The prevalence of the heterozygosity for the IVS1 ϩ 1G3 A GHRH-R mutation was lower than what we had expected by calculation and did not differ in young (4.16%; 10 males and nine females) and old individuals (5.04%; seven males and 10 females). With prevalence of 4.16% in the younger subjects, we had 0.8 power to detect a difference of 5.24%. These results suggest that heterozygosity for this mutation is not associated with changes in longevity.
Discussion
The question of whether GHD is associated with increased or decreased mortality is highly debated. Rosén's report (14) of increased mortality in hypopituitary patients was interpreted by some investigators as an indication of the detrimental effects of GHD on life expectancy. Subsequently, Besson et al. (17) studied the life span of a family with several subjects with untreated congenital IGHD due to GH-1 gene deletion (causing complete absence of GH) that lived in the 19th and 20th centuries and found that IGHD was associated with reduced life expectancy. However, other studies, including a large epidemiological study of 1014 hypopituitary patients (18), did not find evidence of GHD association with increased mortality, although this may also have been due to the fact that only 115 of the patients had been tested for GHD. In the latter study, independent risk factors for excess mortality were female sex, craniopharyngioma, and untreated gonadotropin deficiency. Furthermore, most animal studies (2-8) associate GHD or GH resistance with increased longevity, and reduced IGF-I signaling has been shown in human centenarians (11) .
The only way to answer the question of whether untreated GHD influences longevity in humans is provided by experiments of nature, as done previously by Besson et al. (17) . One of the largest ones is the IGHD kindred of Itabaianinha. The affected individuals represent the human equivalent of animal models of IGHD that scientists have worked hard to develop. Here we demonstrate that the risk of death is not significantly different between the Itabaianinha kindred IGHD subjects and their normalstature siblings. The main difference between the data reported by us and by Besson et al. (17) and some of those published so far is that the IGHD individuals in Besson's and our report have severe, lifelong, and untreated IGHD, whereas previously reported epidemiological studies mostly included patients with hypopituitarism after surgery and/or radiotherapy for pituitary tumors, with likely variable degrees of GHD (14, 19 -21) . A nationwide Danish study (21) included 1794 hypopituitary individuals, mostly with acquired, adult-onset GHD. They found that mortality was increased in childhood-onset GHD (HR ϭ 8.3 in males and 9.4 in females) due to cancer, and in adult-onset GHD (HR ϭ 1.9 in males and 3.4 in females) due to cancer in both genders and to circulatory diseases in females and in males above 65 yr of age. It is possible that the increased rate of malignancy-related deaths can be explained by factors other than their hypopituitarism, like pituitary surgery and radiation (22) , multiple neoplasias (20) , higher risk of second cancer (23) , and a mitogenic role of GH treatment, especially with older high-dosage regimens (24) . The modest albeit significant increase in vascular mortality was restricted to women and older men, and the authors emphasized that a "conclusion on the impact of GHD per se on mortality is not feasible." As a whole, the previous published literature does not firmly support the concept that GHD reduces longevity, because it is well known that the suboptimal (or excessive) replacement of other hormones (glucocorticoid, thyroid, and sex hormones) can influence several metabolic parameters that can impact vascular risk.
On the other hand, this consideration cannot be applied to the subjects reported by Besson et al. who also had IGHD. The reason for different findings in the two populations can only be speculated. Differently from subjects with large homozygous deletions in the GH-1 gene reported by Besson et al. (17) , our subjects have measurable (albeit very low) serum GH levels (15) . Furthermore, different genetic backgrounds (possibly associated with modifying genes) and very different environment and food intake (mountains of Switzerland vs. tropical northeast Brazil), and different historical period of observation are all factors likely to interact with the GHD status in determining longevity.
Our data show that a minimal GH secretion since birth can be enough to attain normal longevity. However, the life span of our IGHD individuals is shorter than the general population, but this difference is driven by the high frequency of early deaths (before age 20) in female IGHD. Once IGHD individuals reach adulthood, there is no difference in their life span compared with siblings or the general population, suggesting that IGHD is not a risk factor for cardiovascular mortality in middle or advanced age. It has to be pointed out that we may have missed IGHD deaths that occurred in very young IGHD individuals, before the phenotype of short stature could be clearly evident. Such additional deaths would not alter our conclusion of normal life expectancy once adulthood is reached.
The gender discrepancy in deaths was also reported in IGHD subjects (17) , and in two studies of patients with hypopituitarism (18, 21) . It was hypothesized that simultaneous lack of GH and estrogen could explain the increase in vascular deaths. Because the excess death of our cohort was in females under age 20, and the age of menarche IGHD women of Itabaianinha is delayed (17.6 Ϯ 2.2 yr) (25) , one could also advocate a role of the simultaneous lack of GH and estrogen. However, when we looked at the causes of these five early deaths, one official certificate reported an infectious cause, but verbal reports from family members suggested dehydration due to diarrheal diseases in the remainders. Therefore, vascular risk is unlikely to be involved. Although IGHD individuals from Itabaianinha do not present hypoglycemia in infancy (26) , one could hypothesize that the lack of GH may make these subjects more vulnerable to the effects of diarrhea-induced dehydration. Furthermore, the GH/IGF-I axis affects the immune system by increasing lymphopoiesis and granulopoiesis and by inhibiting apoptosis of granulocytes (27) . Interestingly, body surface area-corrected spleen volume is reduced in these IGHD individuals (28) , suggesting that immune function may be influenced by severe lack of GH. Why this excess death occurs more in females than in males remains unclear. Given the excess mortality in young females, the adult female cohort includes survivors of the early death risk.
When we looked at the causes of death, we found no significant difference between IGHD and the general population. Although the accuracy of these data may be suboptimal, it is noteworthy to underline the similar rate of cardiovascular deaths between IGHD and the general population, despite the fact that IGHD individuals are exposed from childhood to cardiovascular risk factors such as increased abdominal adiposity, increased serum LDL cholesterol and C-reactive protein, and elevated systolic blood pressure in adults (29 -31) . The Bogalusa Heart Study showed that childhood obesity and increase in LDL cholesterol are predictors of carotid atherosclerosis and coronary events (32) , but this does not seem to apply to IGHD individuals (33).
Although we have only one cancer death in the IGHD group, the rate of cancer death in IGHD individuals was not different from the general population. Several reports have shown an epidemiological association between activity of the GH/IGF-I axis and neoplasms of breast (34), cervix (35) , prostate (36) , and colon (37) . Furthermore, recently no cases of cancer were registered in 222 congenital IGF-I-deficient individuals aged 3 to 78 yr, whereas 9 to 24% of their member families had a malignancy (38) , suggesting that congenital IGF-I deficiency can protect against the appearance of cancer. In Rosén's paper (14) , seven hypopituitary patients (three males and four females) died from cancer (expected 10.1 and 4.1; P Ͻ 0.02 and P Ͻ 0.056), also suggesting that the mortality for cancer in their hypopituitary group was lower than expected. Our report of one confirmed cancer death in an individual with congenital IGHD shows that the protection against cancer by GHD is not absolute. An inverse correlation between body size and longevity has been reported in several animal species (2) (3) (4) (5) (6) (7) (8) (9) (10) . These findings are difficult to reconcile with the disabling manifestations of somatopause. Possible explanations are related to the divergent physiological roles of GH during different stages of life. Long-term survival presumably confers little or no reproductive, and thus evolutionary, advantage. Robust somatotropic signaling early in life may have been selected to guarantee sexual maturation and reproductive fitness, regardless of the "costs" in terms of longevity and age-related disease (5). Our IGHD patients balance a satisfactory reproductive life, although moderately shortened in females (25) , with a normal longevity. They exhibit throughout life severe reduction of serum IGF-I and IGF-I binding protein type 3 (IGFBP-3), such that the ratio of total IGF to IGFBP-3 is higher than controls (39) . A similar pattern was found in healthy centenarians (40) . A high plasma IGF-I/IGFBP-3 molar ratio might improve insulin action and plasma lipid concentration in centenarians or counteract the adverse lipid profile in IGHD.
Because adult heterozygous have normal height and serum IGF-I levels, their mild phenotype might reflect a reduction in GH secretion not sufficient to impair final height, but sufficient to improve insulin sensitivity (16) . Because insulin sensitivity is a hallmark of human centenarians (40), we had hypothesized that heterozygous individuals may live longer than the homozygous normal subjects and that we would find a higher percentage of heterozygous subjects in older individuals. However, heterozygous carriers are equally represented in young and older age groups, suggesting no effect of monoallelic GHRH-R mutation on longevity.
Our study has obvious limitations due to its retrospective nature and to the relatively low number of subjects, particularly when compared with previously published population-based studies of hypopituitary patients (14, 18, 19) . It is therefore possible that we lacked the power to detect a small increase in mortality. Nevertheless, we believe that this unique population provides important additional information on the interaction between IGHD and life expectancy.
In conclusion, differently for a previously published paper (17) , our data do not seem to support the concept that IGHD compromises longevity. The multiple differences (age of onset and severity of GHD, unique and selected genetic background, and rural environment) limit the applicability of our findings to subjects with acquired, adult-onset GHD residing in different geographical areas.
